Class 1 and class 3 aldehyde dehydrogenase levels in the human tumor cell lines currently used by the National Cancer Institute to screen for potentially useful antitumor agents

Advances in Experimental Medicine and Biology

Volumn 414, Issue , 1997, Pages 81-94

  Sreerama, Lakshmaiah ^a   Sladek, Norman E ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE; ANTINEOPLASTIC AGENT; ISOENZYME;

ANTINEOPLASTIC ACTIVITY; CELL LEVEL; CONFERENCE PAPER; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME CHEMISTRY; ENZYME SYNTHESIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TUMOR CELL LINE;

ALDEHYDE DEHYDROGENASE; ANTINEOPLASTIC AGENTS; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; ISOENZYMES; MALE; NATIONAL INSTITUTES OF HEALTH (U.S.); TUMOR CELLS, CULTURED; UNITED STATES;

EID: 0030961976     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Conference Paper

References (16)

1. Boyd, M.R. and Paull, K.D.: Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Devel. Res., 34 (1995) 91-109.
2. Chang, T.K.H., Weber, G.F., Crespi, C.L. and Waxman, D.J.: Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res., 53 (1993) 5629-5637.
3. Dockham, P.A., Lee, M.-O. and Sladek, N.E.: Identification of human liver aldehyde dehydrogenases that catalyze the oxidation of aldophosphamide and retinaldehyde. Biochem. Pharmacol., 43 (1992) 2453-2469.
4. Fitzsimmons, S. A., Workman, P., Grever, M., Paull, K., Camalier, R. and Lewis, A. D.: Reductase enzyme expression across the National Cancer Institute tumor cell line panel: correlation with sensitivity to mitomycin C and EO9. J. Natl. Cancer Inst., 88 (1996) 259-269.
5. Hombeck, P., Winston, S.E. and Fuller, S.A.: Enzyme-linked immunosorbent assays (ELISA). In Ausubel, F.M., Brent. R., Kingston, R.E., Moore, D.D., Seidman, J.G., Smith, J.A. and Struhl, K. (Eds.), Current Protocols in Molecular Biology, Greene Publishing Associates and Wiley-Interscience, N. Y., 1991, pp 11.2.1-11.2.22.
6. Lee, J.-S., Paull, K., Alvarez, M., Hose, C., Monks, A., Grever, M., Tito Fojo, A. and Bates, S.E.: Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. Mol. Pharmacol., 46 (1994) 627-638.
7. Monks, A., Scudiero, D., Skehan, P., Shoemaker, R., Paull, K., Vistica, D., Hose, C., Langley, J., Cronise, P., Vaigro-Wolff, A., Gray-Goodrich, M., Campbell, H., Mayo, J. and Boyd, M.: Feasibility of a high-flux anti-cancer drug screen using a diverse panel of cultured human tumor cell lines. J. Natl. Cancer Inst., 83 (1991) 757-766.
8. Paull, K.D., Shoemaker, R.H., Hodes, L., Monks, A., Scudiero, D.A., Rubinstein, L., Plowman, J. and Boyd, M.R.: Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J. Natl. Cancer Inst., 81 (1989) 1088-1092.
9. Sladek, N.E.: Oxazaphosphorine-specific acquired cellular resistance. In Teicher, B.A. (Ed.), Drug Resistance in Oncology, Marcel Dekker, N.Y., 1993, pp. 375-411.
10. Sladek, N.E.: Metabolism and pharmacokinetic behavior of cyclophosphamide and related oxazaphosphorines. In Powis, G. (Ed.), Anticancer Drugs: Reactive Metabolism and Drug Interactions, Pergamon Press, United Kingdom, 1994, pp. 79-156.
11. Sladek, N.E. and Lee, M.-O.: The use of immortalized mouse L1210/OAP cells established in culture to study the major class 1 aldehyde dehydrogenase-catalyzed oxidation of aldehydes in intact cells. Adv. Exp. Med. Biol., 328 (1993) 51-62.
12. Sladek, N.E. and Sreerama, L.: Cytosolic class-3 and class-1 aldehyde dehydrogenase activities (ALDH-3 and ALDH-1, respectively) in human primary breast tumors. Proc. Am. Assoc. Cancer Res., 36 (1995) 325.
13. Sreerama, L. and Sladek, N.E.: Identification and characterization of a novel class 3 aldehyde dehydrogenase overexpressed in a human breast adenocarcinoma cell line exhibiting oxazaphosphorine-specific acquired resistance. Biochem. Pharmacol., 45 (1993) 2487-2505.
14. Sreerama, L. and Sladek, N.E.: Identification of a methylcholanthrene-induced aldehyde dehydrogenase in a human breast adenocarcinoma cell line exhibiting oxazaphosphorine-specific acquired resistance. Cancer Res., 54 (1994) 2176-2185.
15. Sreerama, L. and Sladek, N.E.: Overexpression of glutathione S-transferases, DT-diaphorase and an apparently tumor-specific cytosolic class-3 aldehyde dehydrogenase by Warthin tumors and mucoepidermoid carcinomas of the parotid gland. Arch. Oral Biol., 41 (1996) In press.
16. Uckun, F.M., Chandan-Langlie, M., Dockham, P.A., Aeppli, D. and Sladek N.E.: Sensitivity of primary clonogenic blasts from acute lymphoblastic leukemia patients to an activated cyclophosphamide, viz., mafosfamide. Leukemia and Lymphoma, 13 (1994) 417-428.